Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small ...

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response rates of up to 90% in patients treated with Ibtrozi for locally advanced or ...

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...

The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the ...

Nuvation Bio (NYSE:NUVB) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral ...

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.